JPWO2021081407A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021081407A5
JPWO2021081407A5 JP2022523574A JP2022523574A JPWO2021081407A5 JP WO2021081407 A5 JPWO2021081407 A5 JP WO2021081407A5 JP 2022523574 A JP2022523574 A JP 2022523574A JP 2022523574 A JP2022523574 A JP 2022523574A JP WO2021081407 A5 JPWO2021081407 A5 JP WO2021081407A5
Authority
JP
Japan
Prior art keywords
alkyldiyl
peg
amino
pep
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022523574A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022553702A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/057167 external-priority patent/WO2021081407A1/en
Publication of JP2022553702A publication Critical patent/JP2022553702A/ja
Publication of JPWO2021081407A5 publication Critical patent/JPWO2021081407A5/ja
Pending legal-status Critical Current

Links

JP2022523574A 2019-10-25 2020-10-23 チエノアゼピン、イムノコンジュゲート、及びそれらの使用 Pending JP2022553702A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962926333P 2019-10-25 2019-10-25
US62/926,333 2019-10-25
US202062984184P 2020-03-02 2020-03-02
US62/984,184 2020-03-02
PCT/US2020/057167 WO2021081407A1 (en) 2019-10-25 2020-10-23 Thienoazepine immunoconjugates, and uses thereof

Publications (2)

Publication Number Publication Date
JP2022553702A JP2022553702A (ja) 2022-12-26
JPWO2021081407A5 true JPWO2021081407A5 (es) 2023-10-20

Family

ID=73544268

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022523574A Pending JP2022553702A (ja) 2019-10-25 2020-10-23 チエノアゼピン、イムノコンジュゲート、及びそれらの使用

Country Status (11)

Country Link
US (2) US11654199B2 (es)
EP (1) EP4048315A1 (es)
JP (1) JP2022553702A (es)
KR (1) KR20220088901A (es)
AU (1) AU2020369652A1 (es)
BR (1) BR112022007719A2 (es)
CA (1) CA3155077A1 (es)
IL (1) IL292396A (es)
MX (1) MX2022004875A (es)
TW (1) TW202128226A (es)
WO (1) WO2021081407A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3484518A4 (en) 2016-07-07 2020-04-22 The Board of Trustees of the Leland Stanford Junior University ANTIBODY ADJUVANT CONJUGATES
WO2020190725A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
JP2023524271A (ja) * 2020-05-08 2023-06-09 ボルト バイオセラピューティクス、インコーポレーテッド エラスターゼ－基質ペプチドリンカーイムノコンジュゲート、及びそれらの使用
WO2022036101A1 (en) * 2020-08-13 2022-02-17 Bolt Biotherapeutics, Inc. Pyrazoloazepine immunoconjugates, and uses thereof
WO2023076599A1 (en) * 2021-10-29 2023-05-04 Bolt Biotherapeutics, Inc. Tlr agonist immunoconjugates with cysteine-mutant antibodies, and uses thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US723288A (en) 1901-10-26 1903-03-24 Harry South Lewis Cipher-key for cryptographic codes.
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
US5874540A (en) 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
DE69907439T3 (de) 1998-05-06 2014-01-02 Genentech, Inc. Reinigung von proteinen durch ionenaustauschchromatographie
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US7416726B2 (en) 2000-04-13 2008-08-26 The Rockefeller University Enhancement of antibody-mediated immune responses
US7273608B2 (en) 2004-03-11 2007-09-25 City Of Hope Humanized anti-CEA T84.66 antibody and uses thereof
CN101065151B (zh) 2004-09-23 2014-12-10 健泰科生物技术公司 半胱氨酸改造的抗体和偶联物
US20070014795A1 (en) 2004-12-30 2007-01-18 Dhodapkar Madhav V Compositions and methods for enhanced dendritic cell maturation and function
EP2455100A3 (en) 2005-11-07 2012-11-07 The Rockefeller University Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof
JP5399712B2 (ja) 2005-12-21 2014-01-29 アムゲン リサーチ （ミュンヘン） ゲーエムベーハー 可溶性ｃｅａに対する抵抗性を有する医薬組成物
AU2008251608B2 (en) 2007-05-08 2014-03-27 Genentech, Inc. Cysteine engineered anti-MUC16 antibodies and antibody drug conjugates
BRPI0818780A2 (pt) 2007-10-19 2015-04-22 Genentech Inc Anticorpo anti-tenb2 planejados por cisteína e conjugados de medicamento com anticorpos
RU2016125705A (ru) 2009-08-18 2018-12-04 Вентиркс Фармасьютикалз, Инк. Замещенные бензоазепины в качестве модуляторов тoll-подобных рецепторов
CN102822199B (zh) 2010-02-04 2014-10-15 东丽株式会社 癌的治疗和/或预防用药物组合物
CA2816426A1 (en) 2010-11-17 2012-06-07 Genentech, Inc. Alaninyl maytansinol antibody conjugates
PL2681244T3 (pl) 2011-03-02 2018-04-30 Roche Glycart Ag Przeciwciała przeciwko antygenowi rakowo-płodowemu
MX348578B (es) 2011-08-04 2017-06-20 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
PL2740793T3 (pl) 2011-08-04 2018-04-30 Toray Industries, Inc. Kompozycja leku do leczenia i/lub zapobiegania nowotworowi
WO2013018889A1 (ja) 2011-08-04 2013-02-07 東レ株式会社 癌の治療及び／又は予防用医薬組成物
CA2844030C (en) 2011-08-04 2019-09-03 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
AU2013223137B2 (en) 2012-02-21 2017-10-19 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
AU2013223161B2 (en) 2012-02-21 2017-10-19 Toray Industries, Inc. Medicinal composition for treating and/or preventing cancer
IN2014KN01713A (es) 2012-02-21 2015-10-23 Toray Industries
AU2013223147B2 (en) 2012-02-21 2017-10-05 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
US9753038B2 (en) 2012-07-19 2017-09-05 Toray Industries, Inc. Method for detecting cancer via measurement of caprin-1 expression level
CA2879304C (en) 2012-07-19 2020-07-14 Toray Industries, Inc. Method for detecting cancer
EA039377B1 (ru) 2012-11-20 2022-01-20 Санофи Антитела к ceacam5 и их применения
AU2014303375B2 (en) 2013-08-09 2019-07-04 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
PE20210168A1 (es) 2014-02-10 2021-01-28 Merck Patent Gmbh INHIBICION DIRIGIDA DEL FACTOR DE CRECIMIENTO TRANSFORMADOR ß (TGFß)
PE20170782A1 (es) 2014-11-21 2017-07-04 Bristol Myers Squibb Co Anticuerpos frente a cd73 y usos de los mismos
KR20190075921A (ko) 2016-10-28 2019-07-01 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
EP3574018A4 (en) * 2017-01-27 2020-10-07 Silverback Therapeutics, Inc. CONJUGATES TARGETING TUMORS AND THEIR METHODS OF USE
JP2021524447A (ja) * 2018-05-17 2021-09-13 ボルト バイオセラピューティクス、インコーポレーテッド イムノコンジュゲート
CA3143156A1 (en) 2019-06-13 2020-12-17 Bolt Biotherapeutics, Inc. Macromolecule-supported aminobenzazepine compounds
AU2020291014A1 (en) 2019-06-13 2022-01-27 Bolt Biotherapeutics, Inc. Aminobenzazepine compounds, immunoconjugates, and uses thereof
US20230257393A1 (en) 2019-10-25 2023-08-17 Bolt Biotherapeutics, Inc. Macromolecule-supported thienoazepine compounds, and uses thereof

Similar Documents

Publication Publication Date Title
JPWO2020252294A5 (es)
JP2683080B2 (ja) トリ‐アザ大環状化合物及びそれらの金属錯体
JP2021506883A (ja) ピロロベンゾジアゼピン抗体結合体
CN112752759A (zh) 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物及其方法与用途
JP2020512270A5 (es)
JPH02501141A (ja) テトラ‐アザ大環状化合物およびその金属錯体
JP2021503450A5 (es)
JPWO2021067242A5 (es)
KR20140139480A (ko) 항체-약물 접합체 및 관련 화합물, 조성물, 및 방법
JP6704900B2 (ja) ポリオキサゾリン抗体薬物複合体
JP7023933B2 (ja) セコ－シクロプロパピロロインドール化合物、その抗体－薬物コンジュゲート、ならびに製造および使用方法
EP3600444A1 (en) HDAC INHIBITORS-BASED ANTIBODY DRUG CONJUGATES (ADCs) AND USE IN THERAPY
JP2020530007A5 (es)
JP2020534300A5 (es)
KR20180033533A (ko) 치료제를 전달하기 위한 pH-민감성 링커
JP2019537622A (ja) 非線状自壊性リンカーおよびそのコンジュゲート
JP2019535710A (ja) Ｐｅｇｍｅｍａ及び薬物担持ポリマーセグメントから構成される自己集合化ジブロックコポリマー
JPWO2021081407A5 (es)
IL273387B2 (en) Thylanstatin analogs
JP2023011567A (ja) システイン改変抗体－毒素複合体（ｔｄｃ）の部位特異的結合サイトのスクリーニング
JPWO2021226440A5 (es)
JPWO2021081402A5 (es)
JP5612467B2 (ja) Ｆｍｏｃをベースとした加水分解性リンカーの調製方法
JPWO2019213445A5 (es)
JPWO2019232449A5 (es)